Oral bemnifosbuvir (AT-527) vs placebo inpatients with mild-to-moderate COVID-19 inan outpatient setting (MORNINGSKY): supplementary data

Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir,a novel, oral nucleotide analog to treat COVID-19. Patients & methods: Outpatient adults/adolescentswith mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to symptomalleviation/improvement (primary outcome), risk of hospitalization/death, viral load and safety wereevaluated. Results: Although the study was discontinued prematurely and did not meet its primary endpoint, bemnifosbuvir treatment resulted in fewer hospitalizations (71% relative risk reduction), COVID-19-related medically attended hospital visits, and COVID-19-related complications compared with placebo.No reduction in viral load was observed. The proportion of patients with adverse events was similar; nodeaths occurred. Conclusion: Bemnifosbuvir showed hospitalization reduction in patients with variabledisease progression risk and was well tolerated.